• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 3/27/24: Patients Hate ‘Forever’ Drugs—Is Wegovy Different? Low Melatonin Can Increase Risk of Neurological Disorders & more


The latest news for pharma industry insiders.

The State of the Opioid Epidemic

In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.

Low Melatonin in the Gut Can Increase Risk of Neurological Disorders

Melatonin is linked to circadian rhythm, mitochondrial function, and neuroinflammation.

Patients Hate ‘Forever’ Drugs. Is Wegovy Different?

The new obesity drugs might be an exception to a chronic, deadly problem: the failure to stick with medication.

Virtual Second Opinions Save Over $8,700 Per Patient, New Analysis Finds

Third-party research confirms significant impact of specialty expertise on patients’ quality of life and costs across the healthcare continuum

Jenna Phillips on LinkedIn:

The second article in our #DOLs series is now live on Pharmaceutical Executive! Discover how to find the perfect #operatingmodelfor DOLs in your organization.

While DOLs and influencers are often used in #marketingcampaigns, there are many other ways to leverage their expertise. From #medicalaffairs to #clinops and #patientadvocacy, we explore the possibilities. Plus, we share insights on setting realistic #KPIsand identifying flexible engagement models for success.

Check it out here:https://lnkd.in/eKARKwa2

cc.Erik Moen & PA Consulting

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs